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Background
Chagas disease is a parasitosis caused by the protozoan
Trypanosoma cruzi. It is endemic in Latin America, never-
theless it has spread to other regions of the world due to
migration. Up to 30% of the infected patients progress to
the chronic phase, with a 5-year mortality of 50% due to
heart failure or ventricular arrhythmias. We aimed to
compare ventricular function and delayed enhancement
(DE) according to the predominant clinical presentation in
Chronic Chagas disease (CCD) either ventricular tachycar-
dia (VT) or heart failure (HF), as well as to compare CCD
with the undetermined and subclinical phases.
Methods
Fifty-one patients with serologic diagnosis of Chagas dis-
ease underwent cardiac magnetic resonance (CMR) from
2009 to 2014 at our institution. Patients were classified as
undetermined, subclinical and CCD, according to clinical,
EKG and echocardiographic findings. CCD patients were
further subdivided according to the predominant clinical
presentation into those with VT or HF.
Results
Out of 51 patients, 6 were classified as undetermined, 5
subclinical and 40 with CCD (21 VT and 19 HF). Myocar-
dial scar expressed as mass and percentage of myocardium
was similar between patients with VT and those with HF
(44.5 ± 20.1 g. vs. 48.6 ± 30.5 g. p=0.62 and 43.8 ± 13% vs.
46.4 ± 19.9%, p=0.64 respectively). There was significant
difference in DE distribution, basal lateral wall (both ante-
rolateral and inferolateral) was affected in 91% of patients
with VT compared to 55% of those with HF, p=0.02.
Patients with VT had higher left ventricular ejection
fraction than patients with HF (36.3 ± 10.9% vs. 23.5 ±
10.6%, p <0.001) and lower end-systolic volume [99 ml
(IQR 75-158) vs 153 ml, (82-193); p = 0.02]. Compared
with HF patients those with VT had higher right ventricu-
lar ejection fraction [43% (31-49) vs 26% (18-45); p = 0.03]
and lower right end-diastolic and end-systolic volumes [68
ml (58-96) vs 100 ml (71-171), p = 0.01 and 36 ml (32-67)
vs 68 ml I (42-129), p = 0.004 respectively].
Conclusions
There was no significant difference in DE burden between
patients with VT or HF in CCD; however the DE distribu-
tion was significantly different, with the lateral wall more
frequently involved in VT group. HF patients had biventri-
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Figure 1
Table 1 Differences according predominant to clinical presentation in Chronic Chagas Disease.
With VT (n=21) Witout VT (n= 19) p
Male sex, n(%) 14 (66) 8 (42) 0.20
Age (years) 58.5 ± 12.7 55.6 ± 13.4 0.48
EDLVD (mm) 57 (54-76) 63 (57-69) 0.08
ESLVD (mm) 46 (40-61) 54 (48-64) 0.14
LVEF(%) 36.3 ±10.9 23.5 ± 10.6 <0.001
LVEDV (ml ) 165 (148-221) 191 (132-230) 0.16
LVESV (ml) 99 (75-158) 153 (82-193) 0.02
Left Ventricular Mass (g) 88 (85-114) 106 (87-144) 0.13
RVEF (%) 43 (31-49) 26 (18-45) 0.03
RVEDV (ml) 68 (58-96) 100 (71-171) 0.01
RVESV (ml) 36 (32-67) 68 (42-129) 0.004
Ventricular Aneurism n(%) 6 (28) 3 (16) 0.46
Thrombus 1 (5) 6 (32) 0.04
Left Anterior Fascicular Block n(%) 1 (4) 3 (16) 0.33
Segments with delayed enhacement 8.9 ±3.0 9.3 ±3.6 0.69
Fibrosis grade (Cuantitative Delayed Enhacement) (gr) 44.5 ±20.2 48.6 ± 30.5 0.62
Percentage of fibrosis (delayed enhacement %) 43.8 ±13.0 46.4 ± 19.9 0.64
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